Table 1 Baseline characteristics
From: Efficacy and safety of erenumab in women with a history of menstrual migraine
History of Menstrual Migraine | ||||
|---|---|---|---|---|
Placebo N = 83 | Erenumab 70 mg N = 68 | Erenumab 140 mg N = 81 | All Patients N = 232 | |
Age, years, median (range) | 37 (20–49) | 38 (21–50) | 37 (19–50) | 37 (19–50) |
Race, n (%) | ||||
White | 71 (86) | 61 (90) | 77 (95) | 209 (90) |
Black or African American | 3 (4) | 5 (7) | 2 (3) | 10 (4) |
Asian | 4 (5) | 0 (0) | 2 (3) | 6 (3) |
Other | 5 (6) | 2 (3) | 0 (0) | 7 (3) |
Migraine with aura,a n (%) | 48 (58) | 35 (52) | 38 (47) | 121 (52) |
Migraine without aura,a n (%) | 71 (86) | 61 (90) | 72 (89) | 204 (88) |
Received hormonal contraception, n (%) | 20 (24) | 18 (26) | 27 (33) | 65 (28) |
Treatment with migraine-preventive medication, n (%) | ||||
Naïve | 50 (60) | 37 (54) | 48 (59) | 135 (58) |
Prior and/or concomitant use | 33 (40) | 31 (46) | 33 (41) | 97 (42) |
Baseline phase (4 weeks) | ||||
Monthly migraine days, mean (SD) | 8.6 (2.8) | 8.3 (2.4) | 8.4 (2.4) | 8.4 (2.5) |
Monthly acute migraine-specific medication days, mean (SD) | 3.2 (3.5) | 3.1 (3.1) | 3.7 (3.6) | 3.3 (3.4) |
Acute migraine-specific medication use, n (%) | 48 (58) | 38 (56) | 51 (63) | 137 (59) |